SST2-positive Neuroendocrine Neoplasms clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

    open to eligible people ages 18 years and up

    This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

    at UCSF

Our lead scientists for SST2-positive Neuroendocrine Neoplasms research studies include .

Last updated: